This paper on early treatment was the key paper with the treatment algorithm; I wrote with Dr. McCullough & is listed as 2nd author. But you see who is the last author, Zev, he was senior scientist

by Paul Alexander

We had Zev as last author as he was the senior scientist with guidance. It was his work we developed and formulated. He is and was transformational. This tells you his role in early treatment

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Peter A McCullough 1, Paul E Alexander 2, Robin Armstrong 3, Cristian Arvinte 4, Alan F Bain 5, Richard P Bartlett 6, Robert L Berkowitz 7, Andrew C Berry 8, Thomas J Borody 9, Joseph H Brewer 10, Adam M Brufsky 11, Teryn Clarke 12, Roland Derwand 13, Alieta Eck 14, John Eck 14, Richard A Eisner 15, George C Fareed 16, Angelina Farella 17, Silvia N S Fonseca 18, Charles E Geyer Jr 19, Russell S Gonnering 20, Karladine E Graves 21, Kenneth B V Gross 22, Sabine Hazan 23, Kristin S Held 24, H Thomas Hight 25, Stella Immanuel 26, Michael M Jacobs 27, Joseph A Ladapo 28, Lionel H Lee 29, John Littell 30, Ivette Lozano 31, Harpal S Mangat 32, Ben Marble 33, John E McKinnon 34, Lee D Merritt 35, Jane M Orient 36, Ramin Oskoui 37, Donald C Pompan 38, Brian C Procter 39, Chad Prodromos 40, Juliana Cepelowicz Rajter 41, Jean-Jacques Rajter 41, C Venkata S Ram 42, Salete S Rios 43, Harvey A Risch 44, Michael J A Robb 45, Molly Rutherford 46, Martin Scholz 47, Marilyn M Singleton 48, James A Tumlin 49, Brian M Tyson 50, Richard G Urso 51, Kelly Victory 52, Elizabeth Lee Vliet 53, Craig M Wax 54, Alexandre G Wolkoff 55, Vicki Wooll 56, Vladimir Zelenko 57

Affiliations expand

Free article

Abstract

The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death.

Keywords: COVID-19; SARS-CoV-2; ambulatory treatment; anti-infective; anti-inflammatory; anticoagulant; antiplatelet agent; antiviral; corticosteroid; hospitalization; mortality; sequenced multidrug therapy.